MCID: CLS047
MIFTS: 27

Classic Progressive Supranuclear Palsy Syndrome

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Classic Progressive Supranuclear Palsy Syndrome

MalaCards integrated aliases for Classic Progressive Supranuclear Palsy Syndrome:

Name: Classic Progressive Supranuclear Palsy Syndrome 60
Steele-Richardson-Olszewski Disease 60
Progressive Supranuclear Palsy 74
Classic Psp Syndrome 60
Richardson Syndrome 60

Characteristics:

Orphanet epidemiological data:

60
classic progressive supranuclear palsy syndrome
Inheritance: Not applicable; Age of onset: Adult; Age of death: elderly;

Classifications:



External Ids:

ICD10 via Orphanet 35 G23.1
UMLS via Orphanet 75 C0038868
Orphanet 60 ORPHA240071
UMLS 74 C0038868

Summaries for Classic Progressive Supranuclear Palsy Syndrome

MalaCards based summary : Classic Progressive Supranuclear Palsy Syndrome, also known as steele-richardson-olszewski disease, is related to feigenbaum bergeron richardson syndrome and atherosclerosis, premature, with deafness, nephropathy, diabetes mellitus, photomyoclonus, and degenerative neurologic disease, and has symptoms including seizures, tremor and photophobia. An important gene associated with Classic Progressive Supranuclear Palsy Syndrome is MAPT (Microtubule Associated Protein Tau). The drugs Rivastigmine and Minocycline have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and colon.

Related Diseases for Classic Progressive Supranuclear Palsy Syndrome

Diseases related to Classic Progressive Supranuclear Palsy Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 feigenbaum bergeron richardson syndrome 12.1
2 atherosclerosis, premature, with deafness, nephropathy, diabetes mellitus, photomyoclonus, and degenerative neurologic disease 11.2
3 leopard syndrome 11.0
4 supranuclear palsy, progressive, 1 10.1
5 multiple system atrophy 1 9.9
6 parkinson disease, late-onset 9.9
7 corticobasal degeneration 9.9

Graphical network of the top 20 diseases related to Classic Progressive Supranuclear Palsy Syndrome:



Diseases related to Classic Progressive Supranuclear Palsy Syndrome

Symptoms & Phenotypes for Classic Progressive Supranuclear Palsy Syndrome

UMLS symptoms related to Classic Progressive Supranuclear Palsy Syndrome:


seizures, tremor, photophobia, back pain, ophthalmoplegia, pain, headache, bradykinesia, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, forgetful, muscle rigidity, poor mobility

Drugs & Therapeutics for Classic Progressive Supranuclear Palsy Syndrome

Drugs for Classic Progressive Supranuclear Palsy Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rivastigmine Approved, Investigational Phase 3,Phase 2 123441-03-2 77991
2
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
3
Pimavanserin Approved, Investigational Phase 3 706779-91-1 16058810
4
Rasagiline Approved Phase 3 136236-51-6 3052776
5
Riluzole Approved, Investigational Phase 3 1744-22-5 5070
6
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 2, Phase 3,Phase 3 303-98-0 5281915
7 Cholinergic Agents Phase 3,Phase 2
8 Neurotransmitter Agents Phase 3,Phase 2
9 Cholinesterase Inhibitors Phase 3,Phase 2
10 Neuroprotective Agents Phase 3,Phase 2
11 Protective Agents Phase 3,Phase 2,Phase 1
12 Ubiquinone Phase 2, Phase 3,Phase 3
13 Nutrients Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
14 Trace Elements Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
15 Vitamins Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
16 Micronutrients Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable
17 Anti-Bacterial Agents Phase 3
18 Anti-Infective Agents Phase 3
19 Tranquilizing Agents Phase 3,Phase 2,Phase 1
20 Psychotropic Drugs Phase 3,Phase 2,Phase 1
21 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
22 Anticonvulsants Phase 3,Phase 2
23 Serotonin 5-HT2 Receptor Antagonists Phase 3
24 Antipsychotic Agents Phase 3
25 Serotonin Agents Phase 3
26 Serotonin Antagonists Phase 3
27 Antiparkinson Agents Phase 3,Phase 2
28 Monoamine Oxidase Inhibitors Phase 3
29 Excitatory Amino Acids Phase 3
30 Excitatory Amino Acid Antagonists Phase 3
31
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
32
Donepezil Approved Phase 2 120014-06-4 3152
33
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
34
Acetylcarnitine Approved, Investigational Phase 1, Phase 2 3040-38-8 7045767
35
Lithium carbonate Approved Phase 1, Phase 2 554-13-2
36
Droxidopa Approved, Investigational Phase 2 23651-95-8 443940
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2,Not Applicable 59-30-3 6037
38 Anesthetics Phase 1, Phase 2
39 Pharmaceutical Solutions Phase 1, Phase 2,Phase 2
40 Nootropic Agents Phase 2,Phase 1
41 GABA Agents Phase 2
42 Antimanic Agents Phase 2,Phase 1
43 Alpha-lipoic Acid Phase 1, Phase 2
44 Antioxidants Phase 1, Phase 2
45 Vitamin B Complex Phase 1, Phase 2,Not Applicable
46 Folate Phase 1, Phase 2,Not Applicable
47 Vitamin B9 Phase 1, Phase 2,Not Applicable
48 carnitine Phase 1, Phase 2
49 Thioctic Acid Phase 1, Phase 2
50 Antidepressive Agents Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 97)
# Name Status NCT ID Phase Drugs
1 Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Completed NCT01110720 Phase 2, Phase 3 Davunetide;Placebo
2 Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) Completed NCT00382824 Phase 2, Phase 3 CoenzymeQ10
3 Effects of Coenzyme Q10 in PSP and CBD Completed NCT00532571 Phase 2, Phase 3 CoQ10
4 Study About Efficacy and Safety to Treat Multi-System-Atrophy Completed NCT00146809 Phase 3 Minocyline
5 Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy Recruiting NCT02839642 Phase 3 Rivastigmine;Placebo
6 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Recruiting NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
7 Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy Terminated NCT01187888 Phase 3 Rasagiline;Sugar pill
8 Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) Terminated NCT00211224 Phase 3 Riluzole
9 Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism Unknown status NCT01824121 Phase 1, Phase 2
10 Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy Unknown status NCT00139373 Phase 2 donepezil
11 Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy Unknown status NCT00522015 Phase 2 rivastigmine
12 Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine) Completed NCT00385710 Phase 2 valproic acid;Placebo
13 Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy Completed NCT01537549 Phase 1, Phase 2 alpha-lipoic acid and L-acetyl carnitine
14 A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Completed NCT00703677 Phase 1, Phase 2 Lithium
15 Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy Completed NCT00328874 Phase 2 Coenzyme Q10
16 Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy Completed NCT00005903 Phase 2 GDNF & Synchro Med Infusion System
17 Davunetide (AL-108) in Predicted Tauopathies - Pilot Study Completed NCT01056965 Phase 2 davunetide (AL-108, NAP);Placebo nasal spray
18 The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography Completed NCT01824056 Phase 2 18F-FDG
19 An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) Recruiting NCT03391765 Phase 2 ABBV-8E12
20 A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP). Active, not recruiting NCT02985879 Phase 2 placebo;ABBV-8E12
21 Study of BIIB092 in Participants With Progressive Supranuclear Palsy Active, not recruiting NCT03068468 Phase 2 BIIB092;Placebo
22 Novel Neuroimage Study in Tauopathies With Parkinsonism Active, not recruiting NCT03386669 Phase 2 F-18
23 Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism Not yet recruiting NCT03446807 Phase 2 Droxidopa;Placebo Oral Tablet
24 Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy Completed NCT02494024 Phase 1 Single dose C2N-8E12;Single dose placebo
25 Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy Completed NCT02460094 Phase 1 BIIB092;Placebo
26 Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers Completed NCT02167594 Phase 1 18F-AV-1451;florbetapir F18
27 Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects Completed NCT02103894 Phase 1 [18F]T807 ([18F]MNI-777)
28 Open Label Treatment With tDCS for Parkinson's and Related Disorders for Improvement of Speech, Gait and Mood Completed NCT02104401 Phase 1
29 Phase 1 Test-retest Evaluation of [18F]MNI-958 PET Recruiting NCT03545789 Phase 1 [18F]MNI-958
30 Young Plasma Transfusions for Progressive Supranuclear Palsy Active, not recruiting NCT02460731 Phase 1
31 Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 Active, not recruiting NCT03413319 Phase 1 ABBV-8E12
32 A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy Active, not recruiting NCT02422485 Phase 1 Salsalate
33 Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 Active, not recruiting NCT02658916 Phase 1 BIIB092
34 Safety Study of TPI-287 to Treat CBS and PSP Active, not recruiting NCT02133846 Phase 1 TPI 287 2 mg/m2;TPI-287 20 mg/m2;Placebo;TPI-287 6.3 mg/m2
35 Postural Instability in Progressive Supranuclear Palsy Unknown status NCT01563276
36 Foot Mechanical Stimulation for Treatment of Gait and Gait Related Disorders in Parkinson's Disease and Progressive Supranuclear Palsy. Unknown status NCT01815281 Not Applicable
37 Diagnostic and Prognostic Biomarkers in Parkinson Disease Unknown status NCT00653783
38 Parkinson's Disease, Diagnostic Observations (PADDO) Unknown status NCT01249768
39 Validation of DaTscan for Detection of Parkinson Disease Related Disorders Unknown status NCT02138682 l-123 Ioflupane
40 Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and Personalized Unknown status NCT01403519
41 PET/MR Imaging in Patients With Short and Long Standing Parkinson's Disease Unknown status NCT02801110
42 Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy Completed NCT01049399 Not Applicable tideglusib;tideglusib;placebo
43 Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear Palsy Completed NCT02734485 Not Applicable
44 Rehabilitation in Patients With Progressive Supranuclear Palsy Completed NCT02109393 Not Applicable
45 Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls Completed NCT01348061
46 A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy. Completed NCT00605930 Not Applicable
47 Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration Completed NCT01174771
48 Neuropsychological Evaluation for Early Diagnosis of PSP Completed NCT03478124
49 Risk Factors for Progressive Supranuclear Palsy (PSP) Completed NCT00431301
50 Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain Completed NCT03058965 Early Phase 1 [18F]MNI-958;[18F]Florbetapir;DaTscan

Search NIH Clinical Center for Classic Progressive Supranuclear Palsy Syndrome

Genetic Tests for Classic Progressive Supranuclear Palsy Syndrome

Anatomical Context for Classic Progressive Supranuclear Palsy Syndrome

MalaCards organs/tissues related to Classic Progressive Supranuclear Palsy Syndrome:

42
Brain, Eye, Colon, Bone, Testes, Bone Marrow, Cortex

Publications for Classic Progressive Supranuclear Palsy Syndrome

Articles related to Classic Progressive Supranuclear Palsy Syndrome:

# Title Authors Year
1
Progressive supranuclear palsy (Steele-Richardson-Olszewski disease). ( 10621897 )
1999

Variations for Classic Progressive Supranuclear Palsy Syndrome

Expression for Classic Progressive Supranuclear Palsy Syndrome

Search GEO for disease gene expression data for Classic Progressive Supranuclear Palsy Syndrome.

Pathways for Classic Progressive Supranuclear Palsy Syndrome

GO Terms for Classic Progressive Supranuclear Palsy Syndrome

Sources for Classic Progressive Supranuclear Palsy Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....